SEC filing record
Primary Source · SEC.gov

Scorpion Therapeutics, Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-07-162 events: 1 new form d filer, 1 large raiseLast filing 2024-07-16

Raised

$126M

Investors

38

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Scorpion Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on July 16, 2024 in the Biotechnology industry group. The offering claims Rule 506(b) and covers equity. Scorpion Therapeutics, Inc. reported $125,694,186 sold from 38 investors of a $150,000,002 total offering as of the Form D filed July 16, 2024. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is One Winthrop Square, Suite 400, Boston, MA 02110.

Critical Disclosures

What the filings and the regulators have said about this entity that a reader should know first. Each line links to its source. The history, the same event across other issuers, and alerts are in the terminal.

Reporting lapsed · Form D · last filing July 16, 2024

Offering declared to continue beyond a year; annual amendment 13+ months overdue An issuer that stops filing is the case the going-concern flag cannot catch: the report that would have carried it was never filed.

Timeline
Each line is a fact as filed. The history behind it, the same event across other issuers, and an alert on the next one:Open in the terminal Watch this issuer

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001811858
Entity NameScorpion Therapeutics, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer AddressOne Winthrop Square, Suite 400, Boston, MA 02110
Phone(857) 326-5077
Industry / Fund TypeBiotechnology
Securities TypeEquity
First Sale DateJuly 1, 2024
Filing DateJuly 16, 2024
Accession Number0000950123-24-006593
Total Offering Amount$150,000,002
Total Amount Sold$125,694,186
Amount Remaining$24,305,816
Total Investors38
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationIntended to last more than one year
Sales Commissions$0
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)MA
Amendment Count3 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Jul 16, 2024

Critical / warning

0 / 0

2 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

3

dark, lapsed

Latest event New filer · Jul 16, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2024-07-16, and alerts on the next one
  • 3 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-07-16: 10 related persons added and 2 removed against the filing of 2020-12-07; 15 now listed. The names are in the Terminal feed.

Adam Friedman

Executive Officer, Director · Boston, MA

Arjun Goyal

Director · Boston, MA

Jean-Francois Formela

Director · Boston, MA

Otello Stampacchia

Director · Boston, MA

Shelley Chu

Director · Boston, MA

Keith Flaherty

Director · Boston, MA

Oleg Nodelman

Director · Boston, MA

Jeffrey Albers

Director · Boston, MA

Saurabh Saha

Director · Boston, MA

Andrew Fedder

Executive Officer · Boston, MA

Brian Piper

Executive Officer · Boston, MA

Mark Chao

Executive Officer · Boston, MA

Darrin Stuart

Executive Officer · Boston, MA

Amanda Valentino

Executive Officer · Boston, MA

Erica Jackson

Executive Officer · Boston, MA

Questions About Scorpion Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Scorpion Therapeutics, Inc.?

Scorpion Therapeutics, Inc. is a Delaware corporation that filed a Form D with the SEC on July 16, 2024 in the Biotechnology industry group. The filing claims Rule 506(b) for an offering of equity.

Is Scorpion Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Scorpion Therapeutics, Inc. filed a Form D with the SEC on July 16, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $125,694,186 sold to 38 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Scorpion Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Scorpion Therapeutics, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Scorpion Therapeutics, Inc. raised?

Scorpion Therapeutics, Inc. reported $125,694,186 sold from 38 investors of a $150,000,002 total offering as of the Form D filed July 16, 2024.

Who can invest in Scorpion Therapeutics, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Scorpion Therapeutics, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Scorpion Therapeutics, Inc. and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly. Sales commissions are reported as $0 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Scorpion Therapeutics, Inc.?

The Form D lists 15 related persons: Adam Friedman, executive officer, director; Arjun Goyal, director; Jean-Francois Formela, director; Otello Stampacchia, director; Shelley Chu, director; Keith Flaherty, director; Oleg Nodelman, director; Jeffrey Albers, director, and 7 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Scorpion Therapeutics, Inc. located?

The issuer's address on its SEC filings is One Winthrop Square, Suite 400, Boston, MA 02110. Its phone number of record is 857-326-5077. It is organized under the laws of Delaware.

How long is the Scorpion Therapeutics, Inc. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.

What is Scorpion Therapeutics, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.